CEO: Sumit Aggarwal

Advent Contact: Raj Parekh

Platform for generating novel, broad-spectrum, fifth generation macrolide antibiotics

Zikani Therapeutics is using the breakthrough chemistry developed by its Founder, Professor Andy Myers, to synthesise large numbers of entirely novel macrolide structures. It aims to discover safe, orally available novel macrolides with activity against Gram-negative and resistant strains of bacteria.

Advent invested in the Series A in 2016.

Zikani Therapeutics , Inc. Raises $22 Million in Series A Financing